Nova Leap Health Stock Price To Earnings To Growth
NLH Stock | CAD 0.26 0.01 4.00% |
Nova Leap Health fundamentals help investors to digest information that contributes to Nova Leap's financial success or failures. It also enables traders to predict the movement of Nova Stock. The fundamental analysis module provides a way to measure Nova Leap's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nova Leap stock.
Nova | Price To Earnings To Growth |
Nova Leap Health Company Price To Earnings To Growth Analysis
Nova Leap's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Nova Price To Earnings To Growth Driver Correlations
Understanding the fundamental principles of building solid financial models for Nova Leap is extremely important. It helps to project a fair market value of Nova Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Nova Leap's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Nova Leap's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Nova Leap's interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
Competition |
Nova Price Earnings To Growth Ratio
Price Earnings To Growth Ratio |
|
Based on the latest financial disclosure, Nova Leap Health has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Health Care Providers & Services sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all Canada stocks is 100.0% higher than that of the company.
Nova Leap Current Valuation Drivers
We derive many important indicators used in calculating different scores of Nova Leap from analyzing Nova Leap's financial statements. These drivers represent accounts that assess Nova Leap's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Nova Leap's important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 19.9M | 38.3M | 35.9M | 14.3M | 17.5M | 14.3M | |
Enterprise Value | 24.0M | 41.5M | 40.3M | 17.0M | 18.1M | 16.1M |
Nova Fundamentals
Return On Equity | -0.0249 | ||||
Return On Asset | 0.0279 | ||||
Profit Margin | (0.02) % | ||||
Operating Margin | 0.03 % | ||||
Current Valuation | 21.31 M | ||||
Shares Outstanding | 86.21 M | ||||
Shares Owned By Insiders | 40.76 % | ||||
Number Of Shares Shorted | 12.7 K | ||||
Price To Book | 0.84 X | ||||
Price To Sales | 0.85 X | ||||
Revenue | 26.41 M | ||||
Gross Profit | 9.98 M | ||||
EBITDA | 1.23 M | ||||
Net Income | (1.07 M) | ||||
Cash And Equivalents | 1.24 M | ||||
Cash Per Share | 0.02 X | ||||
Total Debt | 3.97 M | ||||
Debt To Equity | 64.80 % | ||||
Current Ratio | 0.58 X | ||||
Book Value Per Share | 0.21 X | ||||
Cash Flow From Operations | 1.41 M | ||||
Short Ratio | 0.72 X | ||||
Earnings Per Share | (0.02) X | ||||
Target Price | 0.6 | ||||
Beta | 1.52 | ||||
Market Capitalization | 23.28 M | ||||
Total Asset | 23.95 M | ||||
Retained Earnings | (1.19 M) | ||||
Working Capital | (10.37 K) | ||||
Net Asset | 23.95 M |
About Nova Leap Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nova Leap Health's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nova Leap using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nova Leap Health based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nova Stock Analysis
When running Nova Leap's price analysis, check to measure Nova Leap's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nova Leap is operating at the current time. Most of Nova Leap's value examination focuses on studying past and present price action to predict the probability of Nova Leap's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nova Leap's price. Additionally, you may evaluate how the addition of Nova Leap to your portfolios can decrease your overall portfolio volatility.